Masitinib in Dogs
Generic: Masitinib
Masitinib is a selective tyrosine kinase inhibitor primarily used as an oral chemotherapy agent for the treatment of non-resectable canine mast cell tumors.
This medication is intended for dogs.
Overview
Masitinib is an oral, potent, and selective tyrosine kinase inhibitor that represents a significant advancement in the targeted treatment of specific canine cancers. Unlike traditional cytotoxic chemotherapy drugs, such as Cisplatin, which work by indiscriminately damaging rapidly dividing cells, masitinib specifically inhibits the c-kit receptor tyrosine kinase. By blocking this signaling pathway, the medication effectively starves the tumor of the signals necessary for growth and survival. It is most commonly employed in dogs with recurrent or non-resectable mast cell tumors that express a mutated or dysregulated c-kit protein. While some clinicians may utilize Toceranib (Palladia) as a similar targeted therapy, masitinib offers a distinct pharmacological profile for veterinary oncologists to consider in personalized treatment plans.
The integration of masitinib into a broader cancer care strategy often involves careful monitoring of disease progression. In cases where the mast cell tumor is resistant to initial treatments, or if other agents like Lomustine (CCNU) are insufficient, masitinib provides a valuable oral alternative that can be managed in the comfort of the home. This targeted approach aims to extend the patient’s lifespan while maintaining a favorable quality of life compared to conventional systemic chemotherapy agents such as Vinblastine. By minimizing systemic damage to healthy tissues, masitinib helps pet owners manage chronic oncology cases more effectively.
Clinical utility also extends to maintenance therapy in patients who have achieved partial responses to other oncology protocols. While drugs like Cyclophosphamide are powerful, they often carry high risks of severe myelosuppression and hemorrhagic cystitis. Masitinib’s more localized impact on cellular signaling pathways serves as a complementary or alternative strategy. It is critical for the veterinary team to conduct thorough diagnostic testing, including mutation analysis of the tumor, to ensure that the patient is a suitable candidate for this specific kinase inhibitor, thereby optimizing the likelihood of a positive clinical response.
What It Treats
- Non-resectable Mast Cell Tumors: Used when surgical removal is not an option for cutaneous mast cell tumors.
- Recurrent Mast Cell Tumors: Indicated for tumors that have returned after initial surgical or medical intervention.
- Grade II/III Mast Cell Tumors: Often utilized in intermediate to high-grade cases that exhibit c-kit receptor mutations.
How It Works
Masitinib acts as a selective inhibitor of the tyrosine kinase receptors, specifically targeting the c-kit receptor. In many canine mast cell tumors, the c-kit receptor becomes constitutively active, meaning it is 'stuck' in an 'on' position that continuously signals the cell to grow and divide unchecked. By binding to this receptor, masitinib effectively blocks the signals sent to the cell nucleus, leading to decreased proliferation and the induction of apoptosis, or programmed cell death, within the malignant mast cells. This targeted mechanism reduces the tumor's ability to thrive without exerting the same degree of broad-spectrum harm to normal, non-cancerous cells that is often seen with traditional chemotherapeutics. Because it is highly selective, it minimizes damage to the bone marrow and digestive tract, though it still requires diligent monitoring for specific side effects related to its mode of action.
Dosage
Dosage is strictly calculated by a veterinary oncologist based on the patient's body weight, typically measured in mg/kg. It is essential to follow the specific prescription provided by your veterinarian. Do not alter the dose, frequency, or duration of treatment without professional guidance, as consistent dosing is critical for maintaining therapeutic plasma levels and preventing tumor resistance.
Administration
Masitinib tablets should be administered orally with food to reduce the risk of gastrointestinal irritation. The tablets should be swallowed whole and never crushed, split, or chewed, as this can expose handlers to the active drug and alter the controlled-release mechanism of the medication. Ensure the dog consumes the entire dose, and consult your veterinarian if a dose is missed or if the dog vomits shortly after administration.
Storage
Store the medication in its original, tightly sealed container at room temperature between 15°C and 30°C (59°F to 86°F). Keep the bottle in a dry location away from direct sunlight, moisture, and heat sources. Always keep the medication securely out of reach of children and pets, as accidental ingestion can lead to serious adverse health consequences.
Contraindications
Masitinib should not be administered to dogs with a known hypersensitivity to the drug or any of its inactive ingredients. It is also contraindicated in patients with severe pre-existing renal insufficiency or significant hepatic impairment, as the drug is metabolized in the liver and excreted through various pathways that may be compromised in these patients. Additionally, caution must be exercised in pregnant or lactating animals, as the potential risks to the fetus or nursing puppies have not been fully established. Veterinarians should conduct baseline blood chemistry, complete blood counts, and urinalysis before initiating therapy to ensure the patient’s organ function is robust enough to handle the medication safely.
Interactions
Masitinib is primarily metabolized by the cytochrome P450 enzyme system in the liver. Consequently, drugs that are potent inducers or inhibitors of these enzymes may alter the concentration of masitinib in the blood, potentially increasing the risk of toxicity or reducing its clinical efficacy. Concurrent administration with other medications that are known to be nephrotoxic or hepatotoxic should be managed with extreme caution. It is imperative to provide your veterinarian with a complete list of all supplements, prescription medications, and over-the-counter products the dog is currently receiving, as these can interfere with the therapeutic outcomes of oncology protocols.
Side Effects
- Gastrointestinal distress (vomiting, diarrhea, or reduced appetite)
- Hypoalbuminemia (low protein levels in the blood)
- Proteinuria (excess protein in the urine)
- Elevated liver enzymes
- Neutropenia (low white blood cell counts)
- Skin and coat changes, including pruritus or alopecia
- Severe protein-losing nephropathy (rare but serious)
Sources & References
Frequently Asked Questions
This information is educational only and not a substitute for professional veterinary advice. Always consult a licensed veterinarian before starting or changing any medication.
